Crit Care:急性呼吸窘迫综合征的肺液生物标志物

2019-02-17 xing.T 网络

由此可见,该荟萃分析提供了肺液生物标志物的排序系统,根据它们与急性呼吸窘迫综合征的诊断或死亡率的关联。本文所示研究中生物标志物的表现可能有助于改善急性呼吸窘迫综合征的诊断和预后。

随着新技术的发展,容易获取下呼吸道标本、支气管肺泡灌洗液和其他肺液在肺病诊断中越来越重要。近日,危重病医学领域权威杂志Critical Care上发表了一篇研究文章,研究人员旨在回顾和总结与急性呼吸窘迫综合征诊断和死亡相关的肺液生物标志物。

研究人员检索了PubMed、Embase、Web of Science和Cochrane图书馆,确定了2018年1月11日之前发表的文献后,研究人员对有风险的患者急性呼吸窘迫综合征诊断的生物标志物和与疾病死亡率相关性进行了荟萃分析。从纳入的研究中,研究人员提取肺液中测量的生物标志物浓度平均值和标准差、急性呼吸窘迫综合征病因、样本量、人口统计学变量、诊断标准、死亡率和获得肺液的方案。通过平均值的比率测量效应大小,然后通过逆方差法使用其自然对数形式合成并且转化以获得合并比率和95%置信区间。

该分析总共确定了1156篇文献,其中包括49篇研究。总磷脂酶A2活性、总蛋白、白蛋白、纤溶酶原激活物抑制剂-1、晚期糖基化终产物的可溶性受体和血小板活化因子、乙酰胆碱的增加与急性呼吸窘迫综合征诊断相关最密切。至于与急性呼吸窘迫综合征死亡相关的生物标志物,死亡患者肺液中白细胞介素-1β、白细胞介素-6、白细胞介素-8、遏制肺癌-16和纤溶酶原激活物抑制剂-1显著增加。Club细胞蛋白和基质金属蛋白酶-9水平的降低与急性呼吸窘迫综合征诊断的几率增加有关,而Club细胞蛋白和白细胞介素-2水平的降低与急性呼吸窘迫综合征死亡率增加的几率相关。

由此可见,该荟萃分析提供了肺液生物标志物的排序系统,根据它们与急性呼吸窘迫综合征的诊断或死亡率的关联。本文所示研究中生物标志物的表现可能有助于改善急性呼吸窘迫综合征的诊断和预后。

原始出处:

Yishan Wang.et al.Lung fluid biomarkers for acute respiratory distress syndrome: a systematic review and meta-analysis.Critical Care.2019.https://doi.org/10.1186/s13054-019-2336-6

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1841364, encodeId=bc25184136493, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Tue May 14 00:53:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431445, encodeId=e0ef1431445b4, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Feb 19 04:53:00 CST 2019, time=2019-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560809, encodeId=566d15608090b, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Tue Feb 19 04:53:00 CST 2019, time=2019-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566818, encodeId=af4315668183b, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Tue Feb 19 04:53:00 CST 2019, time=2019-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582249, encodeId=c842158224952, content=<a href='/topic/show?id=e46f396832b' target=_blank style='color:#2F92EE;'>#呼吸窘迫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39683, encryptionId=e46f396832b, topicName=呼吸窘迫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22be16898890, createdName=12498cf9m40(暂无昵称), createdTime=Tue Feb 19 04:53:00 CST 2019, time=2019-02-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1841364, encodeId=bc25184136493, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Tue May 14 00:53:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431445, encodeId=e0ef1431445b4, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Feb 19 04:53:00 CST 2019, time=2019-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560809, encodeId=566d15608090b, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Tue Feb 19 04:53:00 CST 2019, time=2019-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566818, encodeId=af4315668183b, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Tue Feb 19 04:53:00 CST 2019, time=2019-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582249, encodeId=c842158224952, content=<a href='/topic/show?id=e46f396832b' target=_blank style='color:#2F92EE;'>#呼吸窘迫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39683, encryptionId=e46f396832b, topicName=呼吸窘迫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22be16898890, createdName=12498cf9m40(暂无昵称), createdTime=Tue Feb 19 04:53:00 CST 2019, time=2019-02-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1841364, encodeId=bc25184136493, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Tue May 14 00:53:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431445, encodeId=e0ef1431445b4, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Feb 19 04:53:00 CST 2019, time=2019-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560809, encodeId=566d15608090b, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Tue Feb 19 04:53:00 CST 2019, time=2019-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566818, encodeId=af4315668183b, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Tue Feb 19 04:53:00 CST 2019, time=2019-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582249, encodeId=c842158224952, content=<a href='/topic/show?id=e46f396832b' target=_blank style='color:#2F92EE;'>#呼吸窘迫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39683, encryptionId=e46f396832b, topicName=呼吸窘迫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22be16898890, createdName=12498cf9m40(暂无昵称), createdTime=Tue Feb 19 04:53:00 CST 2019, time=2019-02-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1841364, encodeId=bc25184136493, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Tue May 14 00:53:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431445, encodeId=e0ef1431445b4, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Feb 19 04:53:00 CST 2019, time=2019-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560809, encodeId=566d15608090b, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Tue Feb 19 04:53:00 CST 2019, time=2019-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566818, encodeId=af4315668183b, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Tue Feb 19 04:53:00 CST 2019, time=2019-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582249, encodeId=c842158224952, content=<a href='/topic/show?id=e46f396832b' target=_blank style='color:#2F92EE;'>#呼吸窘迫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39683, encryptionId=e46f396832b, topicName=呼吸窘迫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22be16898890, createdName=12498cf9m40(暂无昵称), createdTime=Tue Feb 19 04:53:00 CST 2019, time=2019-02-19, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1841364, encodeId=bc25184136493, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Tue May 14 00:53:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431445, encodeId=e0ef1431445b4, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Feb 19 04:53:00 CST 2019, time=2019-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560809, encodeId=566d15608090b, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Tue Feb 19 04:53:00 CST 2019, time=2019-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566818, encodeId=af4315668183b, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Tue Feb 19 04:53:00 CST 2019, time=2019-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582249, encodeId=c842158224952, content=<a href='/topic/show?id=e46f396832b' target=_blank style='color:#2F92EE;'>#呼吸窘迫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39683, encryptionId=e46f396832b, topicName=呼吸窘迫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22be16898890, createdName=12498cf9m40(暂无昵称), createdTime=Tue Feb 19 04:53:00 CST 2019, time=2019-02-19, status=1, ipAttribution=)]

相关资讯

Crit Care Med:小儿创伤后急性呼吸窘迫综合征的危险因素

由此可见,该研究首次描述了小儿创伤患者急性呼吸窘迫综合征的发生率和危险因素。在儿科创伤后更好地了解与急性呼吸窘迫综合征相关的危险因素可能有助于医务人员预测其发展并尽早干预以改善严重受伤儿童的预后。

体外膜肺氧合(ECMO)治疗严重急性呼吸窘迫综合征

病例描述 一名患有严重急性呼吸窘迫综合征的男子 Jackson先生是一位正在加强治疗单元(ICU)接受治疗的36岁患者。在住院前,他很健康,没有服用任何药物。他从不抽烟,每周喝三、四瓶啤酒。一周前,他办公室的几位同事得了呼吸道疾病。一天后,他开始发热、寒战、咳嗽和全身乏力。两天前出现意识模糊和迅速进展的呼吸困难,他被送往急诊科救治,由于急性呼吸衰竭,给予紧急气管插管。甲型流感病毒检测呈阳性。

机械通气可以治疗ARDS吗?

通常情况下,急性呼吸窘迫综合征(ARDS)这一临床综合征的治疗包括病因学、病理生理学和临床症状的治疗。病因学治疗专门针对导致ARDS的疾病。病理生理学治疗是控制致病因素引发进一步损害的过程。症状学治疗则主要治疗疾病的实际临床表现。各种致病因素既可以通过生物途径(如细菌),也可以通过物理方式(如酸性物质或烟雾)引起肺内广泛的炎症反应过程,引起水肿(“湿”肺),最终导致我们所定义的ARDS的症状。肺水

急性呼吸窘迫综合征

50年前,Ashbaugh及其同事(Ashaugh所在团队)对12例感染或创伤患者进行研究,这些患者感染或遭受创伤后会出现呼吸急促、难治性低氧血症以及胸片显示弥漫性阴影等现象。在7例死亡的患者中,有6例患者出现了肺泡腔内被覆明显的透明膜。在此之前,肺泡内透明膜被认为是新生儿呼吸窘迫综合征的特异体征。因此,成人(后改为急性)呼吸窘迫综合征(ARDS)这个术语孕育而出。

Lancet respir med:中重度急性呼吸窘迫综合征的新疗法——间充质干细胞注射疗法

骨髓来源的间充质干细胞(MSCs)疗法在急性呼吸窘迫综合征(ARDS)的预临床模型中显现出治疗潜能。在重症ARDS患者中应用MSCs的安全性尚不明确。现研究人员对MSCs用于中重度ARDS患者的安全性进行评估。研究人员开展一前瞻性的双盲多中心随机试验,在USA的5个大学医疗中心招募辅助呼吸的中重度ARDS患者(氧分压/激发氧<27kPa、呼气末正压[PEEP]≥8cmH2O)。按2:1将患者随机分

Crit Care:胸部X线与肺部超声鉴别急性呼吸窘迫综合征的性能比较

由此可见,为了使用柏林定义识别ARDS,胸部X线和肺部超声检查与死亡率同等相关。使用肺部超声的柏林定义有助于识别死亡风险较高的患者,即使这些患者使用胸部X线检查不符合传统的柏林定义。然而,当胸部影像学检查结果不同时,患者的适度重叠检查提示胸部X线和肺部超声检查应该互补而不是互换使用。